Switch theme
Sign up to access all valuation multiples
Synthetic MR AB develops innovative software solutions for Magnetic Resonance Imaging that support shorter exam times and deliver more information to the clinician. Its product is available in different packages. SyMRI IMAGE provides high MRI workflows and enables automatic segmentation of brain tissue, providing objective decision support, MAGiC is a customer-specific version of SyMRI IMAGE marketed and sold by GE Healthcare under a license agreement, SyMRI NEURO includes contrast images, biomarker segmentation, volumetric measurements of brain tissues and quantitative parametric maps, and SyMRI Research Edition includes contrast images, volumetric measurements and quantitative maps to provide more information to the researcher.
2007
40
LTM Revenue $6.5M
LTM EBITDA -$0.8M
$17.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Synthetic MR has a last 12-month revenue (LTM) of $6.5M and a last 12-month EBITDA of -$0.8M.
In the most recent fiscal year, Synthetic MR achieved revenue of $5.7M and an EBITDA of -$0.9M.
Synthetic MR expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Synthetic MR valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $6.5M | XXX | $5.7M | XXX | XXX | XXX |
| Gross Profit | $6.5M | XXX | $6.4M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 111% | XXX | XXX | XXX |
| EBITDA | -$0.8M | XXX | -$0.9M | XXX | XXX | XXX |
| EBITDA Margin | -12% | XXX | -16% | XXX | XXX | XXX |
| EBIT | -$1.8M | XXX | -$2.0M | XXX | XXX | XXX |
| EBIT Margin | -27% | XXX | -35% | XXX | XXX | XXX |
| Net Profit | -$1.6M | XXX | -$1.7M | XXX | XXX | XXX |
| Net Margin | -25% | XXX | -29% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Synthetic MR's stock price is SEK 3 (or $0).
Synthetic MR has current market cap of SEK 185M (or $19.0M), and EV of SEK 166M (or $17.1M).
See Synthetic MR trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17.1M | $19.0M | XXX | XXX | XXX | XXX | $-0.03 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Synthetic MR has market cap of $19.0M and EV of $17.1M.
Synthetic MR's trades at 3.0x EV/Revenue multiple, and -18.6x EV/EBITDA.
Equity research analysts estimate Synthetic MR's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Synthetic MR has a P/E ratio of -11.7x.
See valuation multiples for Synthetic MR and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19.0M | XXX | $19.0M | XXX | XXX | XXX |
| EV (current) | $17.1M | XXX | $17.1M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 3.0x | XXX | XXX | XXX |
| EV/EBITDA | -22.5x | XXX | -18.6x | XXX | XXX | XXX |
| EV/EBIT | -9.8x | XXX | -8.5x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.7x | XXX | -11.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -15.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSynthetic MR's last 12 month revenue growth is 31%
Synthetic MR's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Synthetic MR's rule of 40 is 53% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Synthetic MR's rule of X is 65% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Synthetic MR and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | 31% | XXX | XXX | XXX |
| EBITDA Margin | -12% | XXX | -16% | XXX | XXX | XXX |
| EBITDA Growth | -81% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 53% | XXX | 15% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 65% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 146% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Synthetic MR acquired XXX companies to date.
Last acquisition by Synthetic MR was XXXXXXXX, XXXXX XXXXX XXXXXX . Synthetic MR acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Synthetic MR founded? | Synthetic MR was founded in 2007. |
| Where is Synthetic MR headquartered? | Synthetic MR is headquartered in Sweden. |
| How many employees does Synthetic MR have? | As of today, Synthetic MR has 40 employees. |
| Is Synthetic MR publicy listed? | Yes, Synthetic MR is a public company listed on SAT. |
| What is the stock symbol of Synthetic MR? | Synthetic MR trades under SYNT ticker. |
| When did Synthetic MR go public? | Synthetic MR went public in 2013. |
| Who are competitors of Synthetic MR? | Similar companies to Synthetic MR include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Synthetic MR? | Synthetic MR's current market cap is $19.0M |
| What is the current revenue of Synthetic MR? | Synthetic MR's last 12 months revenue is $6.5M. |
| What is the current revenue growth of Synthetic MR? | Synthetic MR revenue growth (NTM/LTM) is 31%. |
| What is the current EV/Revenue multiple of Synthetic MR? | Current revenue multiple of Synthetic MR is 2.7x. |
| Is Synthetic MR profitable? | Yes, Synthetic MR is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Synthetic MR? | Synthetic MR's last 12 months EBITDA is -$0.8M. |
| What is Synthetic MR's EBITDA margin? | Synthetic MR's last 12 months EBITDA margin is -12%. |
| What is the current EV/EBITDA multiple of Synthetic MR? | Current EBITDA multiple of Synthetic MR is -22.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
